Faculty

Institution

Unit

Venue

David M. Boruta II

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Gynecologic Oncology And Reproductive Medicine

Department Of Gynecologic Research

The University of Texas MD Anderson Cancer Center

NoneDavid M. Boruta Ii is currently serving as a Gynecologic Oncology And Reproductive Medicine faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

David M. Boruta II

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

gynecology gynecologic oncology oncology gynecologic cancers surgery ovarian cancer gynecological surgery surgical oncology cancer care cancer management laparoscopy radiation oncology obstetrics and gynaecology cancer treatment cancer research minimally invasive procedures endometrial cancer clinical endpoint pathology women's health survival analysis gastrointestinal surgery endocrine-related cancers obstetrics intraoperative consultation metastasis surgical pathology tumoral pathology reproductive medicine endocrine oncology cancer disparities cancer risk seer analysis racial disparities hospital readmission tumor biology medicinal research cancer cells surgical education cancer biology prognosis surgical care vulvar cancer laparoendoscopic single-site surgery neoadjuvant chemotherapy discharge factors prognostic determinants endometrioid endometrial cancer urogynecology reproductive health health disparities epidemiology of cancer case-control study elderly women adnexal masses weekly paclitaxel infusion prognostic factors thrombosis obesity surgery reconstructive microsurgery molecular cancer menstrual cycle lymphoid neoplasia lymphatic system multimodality therapy neuroendocrine disorders health care disparities cervical spine clinical evidence prognostic evaluation prognostic biomarkers geriatric urology venous thrombosis radiation therapy case series tumor size

Notable Scholarly Works

Notable Federal Grants

Collaborators

EFFORT2: Combination Ceralasertib (Atri) Plus Olaparib (Parpi) in Women With Platinum Sensitive Homologous Recombination Deficient (Hrd) Ovarian Cancer With Prior Parpi Exposure. International Journal of Gynecological Cancer (2025)

cancer geneticscombination ceralasertibradiation oncologygynecologic oncologygynecologic cancersoncologyoncogenescancer cellscancer treatmentplus olaparibgynecologyovarian cancer

Supplementary Table S3 From Surgical and Blood-Based Minimal Residual Disease in Patients With Ovarian Cancer After First-Line Therapy: Clinical Outcomes and Translational Opportunities. (2025)

supplementary table s3clinical outcomesradiation oncologygynecological surgerygynecologic oncologysurgical oncologygynecologic cancersoncologyclinical endpointcancer treatmentgynecologyovarian cancer

Abstract A077: The Utility of Surgical Minimal Residual Disease After Frontline Treatment for Prognostic and Investigational Opportunities in Advanced Ovarian Cancer. Cancer Research (2024)

Anne KniselyRoni NiteckiJ. Alejandro Rauh-HainR. Tyler HillmanJolyn S. TaylorLois M. RamondettaMichaela O. GrinsfelderLauren P. CobbDavid M. BorutaGwyn RichardsonPamela T. SolimanAaron ShaferShannon N. WestinNicole D. FlemingTravis T. SimsAnil K. SoodPedro T. RamirezKaren H. LuAmir A. Jazaeri

surgerycancer researchfrontline treatmentadvanced ovarian cancerinvestigational opportunitiescancer treatmentovarian cancer

Ev273/#1097 Minimal Residual Disease as a Prognostic Marker and Opportunity for Intervention in Advanced Ovarian Cancer. International Journal of Gynecological Cancer (2024)

Anne KniselyYibo DaiSanghoon LeeRoni Nitecki WilkeJeffrey HowBryan FellmanJolyn TaylorLois RamondettaMichaela GrinsfelderLauren CobbDavid BorutaGwyn RichardsonPamela SolimanAaron ShaferShannon WestinNicole FlemingTravis SimsAnil SoodPedro RamirezKaren LuAmir Jazaeri

minimal residual diseaseprognostic markeradvanced ovarian cancergynecologyovarian cancer

Normal Risk Ovarian Screening Study: 21-Year Update. Journal of Clinical Oncology (2024)

Chae Young HanKaren H. LuGwen CorriganAlexandra PerezSharlene D. KohringJoseph CelestinoDeepak BediEnrique BediaTherese BeversDavid BorutaMatthew CarlsonLaura HolmanLeroy LeedsCara MathewsGeorgia McCannRichard G. MooreMatthew SchlumbrechtBrian SlomovitzDan TobiasYvette Williams-BrownMichael W. BeversJinsong LiuTerrie G. GornetBeverly C. HandyZhen LuJacob S. BediaSteven J. SkatesRobert C. Bast

public healthtreatment and preventiononcologyclinical researchcancer screeningclinical epidemiologyhealth scienceshealth policy

Prognostic Implications of Minimal Residual Disease Detection by Second-Look Laparoscopy and Circulating Tumor Dna Among Patients With Ovarian Cancer After Front-Line Therapy. Gynecologic Oncology (2024)

Anne KniselySanghoon LeeRoni NiteckiJeffrey HowBryan FellmanCarly Bess ScalisePunashi DuttaAdam ElNaggarMinetta LiuJolyn TaylorLois RamondettaMichaela GrinsfelderLauren CobbDavid BorutaGwyn RichardsonPamela SolimanAaron ShaferShannon WestinNicole FlemingTravis SimsAnil SoodPedro RamirezKaren LuAmir Jazaeri

front-line therapysecond-look laparoscopyprognostic implicationsgynecologic oncologygynecologic cancersoncologytumor dnagynecologyovarian cancer

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (Traction).. Journal of Clinical Oncology (2024)

gynecologic oncologycancer immunotherapygynecologic cancersoncologycancer-associated viruscervical canceradvanced cervical cancergynecology

Innovation in Gynecologic Oncology Fellowship Training: Rethinking the Research Year (1207). Gynecologic Oncology (2023)

cancer carecancer educationgynecological surgeryhealth profession trainingnursinggynecologic oncologysurgical educationcancer managementgynecologic cancersoncologyresearch yearmedical educationgynecology

Rf2 Feasibility and Preliminary Results of the First Clinical Trial Targeting Minimal Residual Disease in Patients With Homologous Recombination Proficient (Hrp) Ovarian Cancer. Gynecologic Oncology (2023)

Anne KniselyTravis SimsDonna GriffinLois RamondettaShatoyia CollinsLauren CobbDavid BorutaGwyn RichardsonAnil SoodPedro RamirezKaren LuAmir Jazaeri

minimal residual diseasefirst clinical trialhomologous recombination proficientgynecologic oncologygynecologic cancersoncologygynecologyovarian cancer

Transforming Frontline Therapy in Ovarian Cancer by Focusing on Surgically Documented Minimal Residual Disease After Frontline Treatment (1178). Gynecologic Oncology (2023)

Anne KniselyRoni NiteckiMinghao DangSanghoon LeeBryan FellmanJose Rauh-HainRobert HillmanJolyn TaylorLois RamondettaMichaela GrinsfelderLauren CobbDavid BorutaGwyn RichardsonPamela SolimanAaron ShaferShannon WestinNicole FlemingTravis SimsAnil SoodPedro RamirezKaren LuLinghua WangAmir Jazaeri

surgeryminimal residual diseasefrontline treatmentgynecologic oncologyfrontline therapyoncologycancer treatmentovarian cancer

1
2
3
4
5
11
10 / page

David M. Boruta II

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Gynecologic Oncology And Reproductive Medicine

Department Of Gynecologic Research

The University of Texas MD Anderson Cancer Center

NoneDavid M. Boruta Ii is currently serving as a Gynecologic Oncology And Reproductive Medicine faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

David M. Boruta II

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

cancer geneticscombination ceralasertibradiation oncologygynecologic oncologygynecologic cancersoncologyoncogenescancer cellscancer treatmentplus olaparibgynecologyovarian cancer

Supplementary Table S3 From Surgical and Blood-Based Minimal Residual Disease in Patients With Ovarian Cancer After First-Line Therapy: Clinical Outcomes and Translational Opportunities. (2025)

supplementary table s3clinical outcomesradiation oncologygynecological surgerygynecologic oncologysurgical oncologygynecologic cancersoncologyclinical endpointcancer treatmentgynecologyovarian cancer

Abstract A077: The Utility of Surgical Minimal Residual Disease After Frontline Treatment for Prognostic and Investigational Opportunities in Advanced Ovarian Cancer. Cancer Research (2024)

surgerycancer researchfrontline treatmentadvanced ovarian cancerinvestigational opportunitiescancer treatmentovarian cancer

Ev273/#1097 Minimal Residual Disease as a Prognostic Marker and Opportunity for Intervention in Advanced Ovarian Cancer. International Journal of Gynecological Cancer (2024)

minimal residual diseaseprognostic markeradvanced ovarian cancergynecologyovarian cancer

Normal Risk Ovarian Screening Study: 21-Year Update. Journal of Clinical Oncology (2024)

public healthtreatment and preventiononcologyclinical researchcancer screeningclinical epidemiologyhealth scienceshealth policy

front-line therapysecond-look laparoscopyprognostic implicationsgynecologic oncologygynecologic cancersoncologytumor dnagynecologyovarian cancer

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (Traction).. Journal of Clinical Oncology (2024)

gynecologic oncologycancer immunotherapygynecologic cancersoncologycancer-associated viruscervical canceradvanced cervical cancergynecology

Innovation in Gynecologic Oncology Fellowship Training: Rethinking the Research Year (1207). Gynecologic Oncology (2023)

Anne KniselyTravis SimsDonna GriffinLois RamondettaShatoyia CollinsLauren CobbDavid BorutaGwyn RichardsonAnil SoodPedro RamirezKaren LuAmir Jazaeri

minimal residual diseasefirst clinical trialhomologous recombination proficientgynecologic oncologygynecologic cancersoncologygynecologyovarian cancer

Transforming Frontline Therapy in Ovarian Cancer by Focusing on Surgically Documented Minimal Residual Disease After Frontline Treatment (1178). Gynecologic Oncology (2023)

surgeryminimal residual diseasefrontline treatmentgynecologic oncologyfrontline therapyoncologycancer treatmentovarian cancer

1
2
3
4
5
11
10 / page